Becton Dickinson (NYSE:BDX) said yesterday that it inked an agreement with C. R. Bard (NYSE:BCR) to acquire the medtech company for $317.00 per Bard common share in cash and stock, valuing the deal at $24 billion.
Franklin Lakes, N.J.-based BD said it plans to create a new segment within the company, BD Interventional, to incorporate Bard’s businesses. BD also named Tom Polen as president of BD, effective immediately. Polen, who previously served as the executive VP and president of the company’s medical segment, will oversee the new interventional arm of the company.
Get the full story at our sister site, Drug Delivery Business News.
The post Becton Dickinson to acquire Bard in $24B deal appeared first on MassDevice.
from MassDevice http://ift.tt/2pd0TcS
Cap comentari:
Publica un comentari a l'entrada